Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Combinatorial BCL-2 / BCL2L1 Expression Predicts Clinical Response to Ruxolitinib in Myelofibrosis

Giacomo Coltro, Viola Videschi, Francesca Gesullo, Manjola Balliu, Alessandro M. Vannucchi, Paola Guglielmelli

Blood (2023) 142 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2023-185821

Published: 2023

Journal Articles

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Blood (2022) 140 (Supplement 1): 1797–1799.

https://doi.org/10.1182/blood-2022-157255

Published: 2022

Journal Articles

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Giuseppe Gaetano Loscocco, Raffaella Santi, Carmela Mannarelli, Francesco Mannelli, Francesca Gesullo, Giacomo Coltro, Paola Guglielmelli, Umberto Gianelli, Alessandro M Vannucchi

Blood (2022) 140 (Supplement 1): 9714–9716.

https://doi.org/10.1182/blood-2022-167880

Published: 2022

Journal Articles

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Fabiana Pancani, Ilaria Colugnat, Raffaela Aquila, Elena Nacca, Paolo Cicogna, Francesco Passamonti, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 1788–1789.

https://doi.org/10.1182/blood-2022-156781

Published: 2022

Journal Articles

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

Fiorenza Irushani Vanderwert, Benedetta Sordi, Francesco Mannelli, Boaz Palterer, Francesca Gesullo, Valentina Mecheri, Raffaella Santi, Carmela Mannarelli, Francesca Crupi, Roberta Zanotti, Federica Irene Grifoni, Chiara Elena, Roberta Parente, Massimo Triggiani, Pieri Lisa, Fabio Almerigogna, Paola Guglielmelli, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2021-148154

Published: 2021

Journal Articles

Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics

Francesco Mannelli, MD, Sara Bencini, Benedetta Peruzzi, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, PhD, Francesca Gesullo, BSci, Blerina Jance, Marida Bonetti, Roberto Caporale, Francesco Annunziato, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1668.

https://doi.org/10.1182/blood-2019-125843

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Giada Rotunno, Carmela Mannarelli, Giada Brogi, Annalisa Pacilli, Francesca Gesullo, Francesco Mannelli, Sara Fiaccabrino, Benedetta Sordi, Chiara Paoli, Ilaria Marone, Elisa Rumi, Rossella Manfredini, Giovanni Barosi, Mario Cazzola, Alessandro M. Vannucchi, Paola Guglielmelli

Blood (2019) 133 (26): 2802–2808.

https://doi.org/10.1182/blood.2018879536

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Paola Guglielmelli, MD PhD, Giacomo Coltro, MD, Giuseppe Gaetano Loscocco, MD, Benedetta Sordi, MD, Francesco Mannelli, MD, Chiara Paoli, PhD, Ilaria Marone, PhD, Alessandro Pancrazzi, PhD, Francesca Gesullo, BSci, Carmela Mannarelli, PhD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2018-99-112287

Published: 2018

Journal Articles

Revised DIPSS-Plus: A Composite Clinical, Cytogenetic and Molecular Prognostic System for Primary Myelofibrosis

Ayalew Tefferi, MD, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Francesca Gesullo, MSc, Christy Finke, BS, Francesco Mannelli, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4192.

https://doi.org/10.1182/blood.V130.Suppl_1.4192.4192

Published: 2017

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

Prognotic Impact of Mutations in Systemic Mastocytosis

Lisa Pieri, MD PhD, Giada Rotunno, MSc, PhD, Francesca Gesullo, MSc, Tiziana Fanelli, MSc, Giuditta Corbizi Fattori, MSc, Annalisa Pacilli, PhD, Federica Scarfì, MD, Maria Loredana Iorno, MD, Fabio Almerigogna, MD, Roberto Salerno, MD, Paola Guglielmelli, MD PhD, Roberta Zanotti, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 1953.

https://doi.org/10.1182/blood.V128.22.1953.1953

Published: 2016

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

NARROW

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Combinatorial BCL-2 / BCL2L1 Expression Predicts Clinical Response to Ruxolitinib in Myelofibrosis

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Revised DIPSS-Plus: A Composite Clinical, Cytogenetic and Molecular Prognostic System for Primary Myelofibrosis

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Prognotic Impact of Mutations in Systemic Mastocytosis

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only